kidney cancer

RCC: Two approvals expand options for TKI-refractory patientsFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
New treatment for kidney cancer gets OKFDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma.
AUA 2016: Experts offer guidance on the meetingTo guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Sunitinib vs. everolimus: PFS, toxicity differ in studyIn a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
How renal mass biopsy impacts managementUrology Times SUO internship program member Robert M. Turner, II, MD, reports on a recent presentation by J. Stuart Wolf, Jr., MD, about possible pitfalls of renal mass biopsy.
Renal cancer follow-up: Find the happy mediumNurse practitioner Adele M. Caruso, MSN, CRNP, discusses appropriate timing of follow-up and ponders related health insurance coverage and cancer survivorship issues.
Renal biopsy may alter management in high-risk patientsIn this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
Study appears to refute obesity paradox in kidney cancerIn this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
Opdivo approved for patients with metastatic renal cell carcinomaFDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.